8.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$8.35
Aprire:
$8.38
Volume 24 ore:
342.35K
Relative Volume:
0.08
Capitalizzazione di mercato:
$1.76B
Reddito:
$503.49M
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-32.42
EPS:
-0.26
Flusso di cassa netto:
$-26.89M
1 W Prestazione:
+6.18%
1M Prestazione:
-3.97%
6M Prestazione:
-3.20%
1 anno Prestazione:
+5.91%
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BCRX
Biocryst Pharmaceuticals Inc
|
8.425 | 1.81B | 503.49M | -53.47M | -26.89M | -0.26 |
![]()
ZTS
Zoetis Inc
|
146.80 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
![]()
HLN
Haleon Plc Adr
|
9.485 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
302.24 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
2025-02-25 | Iniziato | Wedbush | Outperform |
2023-11-20 | Ripresa | JP Morgan | Overweight |
2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-02-22 | Aggiornamento | Needham | Hold → Buy |
2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
2021-12-10 | Iniziato | Oppenheimer | Outperform |
2021-08-06 | Downgrade | Jefferies | Buy → Hold |
2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
2021-03-01 | Iniziato | Cowen | Outperform |
2020-09-29 | Ripresa | JP Morgan | Overweight |
2020-06-17 | Iniziato | BTIG Research | Neutral |
2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2018-11-16 | Ripresa | Piper Jaffray | Overweight |
2018-08-08 | Ripresa | JP Morgan | Overweight |
2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2017-12-20 | Iniziato | Barclays | Equal Weight |
2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | Reiterato | FBR Capital | Outperform |
2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize
BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest
BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks
Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News
What is the dividend policy of BioCryst Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastTrack top-performing stocks effortlessly - Jammu Links News
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetCapitalize on emerging industry trends - Jammu Links News
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyMaximize gains with expert analysis - Jammu Links News
How does BioCryst Pharmaceuticals Inc. compare to its industry peersDiscover breakthrough stocks before the crowd - Jammu Links News
Is BioCryst Pharmaceuticals Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStrong return on investment - Jammu Links News
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketBuild wealth steadily with smart stock selection - Jammu Links News
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
What are the technical indicators suggesting about BioCryst Pharmaceuticals Inc.Double or triple returns - Jammu Links News
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree Stock Market Query - Jammu Links News
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest
BioCryst Announces New President Amid Leadership Change - The Globe and Mail
Healthcare Triangle, Inc. shares fall 3.23% after-hours as BioCryst Pharmaceuticals announces CEO transition. - AInvest
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire
BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest
BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - The Globe and Mail
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):